AssetMark Inc’s Design Therapeutics DSGN Stock Holding History

AssetMark Inc’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,325	Closed	-$5.49K	–	1875
2023 Q3	$5.49K	Buy	2,325 +451	+24%	+$2.1K	﹤0.01%	1382
2023 Q2	$11.8K	Buy	1,874 +216	+13%	+$1.32K	﹤0.01%	1277
2023 Q1	$9.57K	Buy	1,658 +547	+49%	+$4.09K	﹤0.01%	1273
2022 Q4	$11.4K	Buy	1,111 +359	+48%	+$4.87K	﹤0.01%	1289
2022 Q3	$13K	Buy	752 +110	+17%	+$2.19K	﹤0.01%	1197
2022 Q2	$9K	Buy	642 +379	+144%	+$5.12K	﹤0.01%	1228
2022 Q1	$4K	Buy	+263	New	+$4.03K	﹤0.01%	1311

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AssetMark Inc's DSGN Position: Q4 2023 in Review

AssetMark Inc sold out of Design Therapeutics (DSGN) in Q4 2023, closing a stake of 2,325 shares — an estimated $5.49K sold.

AssetMark Inc first reported a position in DSGN in Q1 2022 and held it in 7 quarters. The position peaked at $13K in Q3 2022. 88 funds tracked by Wall St. Rank hold DSGN as of Q4 2023.

AssetMark Inc reported no remaining Design Therapeutics position as of Q4 2023 after selling out during the quarter.
AssetMark Inc sold 2,325 Design Therapeutics shares in Q4 2023, an estimated $5.49K.
AssetMark Inc first reported a position in Design Therapeutics in Q1 2022 and held it in 7 quarters.
AssetMark Inc's Design Therapeutics position peaked at $13K in Q3 2022.
88 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2023.

Based on AssetMark Inc's 13F filing for Q4 2023, filed 9 Feb 2024.